Tenascin-C Is Increased in Inflammatory Bowel Disease and Is Associated with response to Infliximab Therapy
Joint Authors
Ning, Longui
Li, Sha
Gao, Jianguo
Ding, Liang
Wang, Chenhui
Chen, Wenguo
Shan, Guodong
Zhang, Fenming
Yu, Jinghua
Xu, Guoqiang
Source
Issue
Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-9, 9 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2019-11-22
Country of Publication
Egypt
No. of Pages
9
Main Subjects
Abstract EN
Tenascin-C (TNC) is an extracellular matrix glycoprotein expressed in response to inflammation and tissue damage.
The role of TNC in patients with inflammatory bowel disease (IBD) is not well understood.
In this study, we analyzed the expression of TNC in the inflamed mucosa of patients with ulcerative colitis (UC) and Crohn’s disease (CD).
Serum TNC levels were determined by the enzyme-linked immunosorbent assay (ELISA), and the levels of TNC in patients with different disease activities were compared.
The expression of TNC was derived from a GEO dataset.
THP-1 cells were stimulated with TNC to evaluate the proinflammatory role of TNC.
We found higher TNC expression in the inflamed mucosa of patients with UC and CD compared with normal controls (NCs).
TNC was mainly expressed in the stromal area of the intestinal mucosa.
The median serum levels of TNC were significantly higher in UC (median 74.1 ng/ml, range 42.6–102.1 ng/ml) and CD (median 59.2 ng/ml, range 44.0–80.9 ng/ml).
We also found that serum TNC levels were correlated with Mayo scores in UC and Crohn’s disease activity index (CDAI) in CD.
Through GSE14580, we demonstrated that patients who were nonresponsive to infliximab treatment had higher mucosal TNC mRNA expression.
High TNC mRNA expression in the inflamed intestinal mucosa was associated with poor response to infliximab therapy in patients with UC.
Furthermore, THP-1 cells stimulated with TNC showed increased expression of IL-6, but not TNF-α, IL-8, MCP-1, or IL-1β.
Thus, increased TNC levels may participate in the pathogenesis of IBD and may serve as a biomarker for disease activity and response to treatment with infliximab.
American Psychological Association (APA)
Ning, Longui& Li, Sha& Gao, Jianguo& Ding, Liang& Wang, Chenhui& Chen, Wenguo…[et al.]. 2019. Tenascin-C Is Increased in Inflammatory Bowel Disease and Is Associated with response to Infliximab Therapy. BioMed Research International،Vol. 2019, no. 2019, pp.1-9.
https://search.emarefa.net/detail/BIM-1123385
Modern Language Association (MLA)
Ning, Longui…[et al.]. Tenascin-C Is Increased in Inflammatory Bowel Disease and Is Associated with response to Infliximab Therapy. BioMed Research International No. 2019 (2019), pp.1-9.
https://search.emarefa.net/detail/BIM-1123385
American Medical Association (AMA)
Ning, Longui& Li, Sha& Gao, Jianguo& Ding, Liang& Wang, Chenhui& Chen, Wenguo…[et al.]. Tenascin-C Is Increased in Inflammatory Bowel Disease and Is Associated with response to Infliximab Therapy. BioMed Research International. 2019. Vol. 2019, no. 2019, pp.1-9.
https://search.emarefa.net/detail/BIM-1123385
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1123385